Here’s what our clients are saying about their completed projects:
“The MDoutlook team provided a succinct, clear, and targeted assessment of what we needed to support the commercial success of our oncology portfolio now and over the long term.”
Large Biopharma Company
“MDoutlook rocks! They delivered a flexible platform in which internal departments and functions in our organization could access in real-time top influencers in the oncology community, as well as evolving changes in oncologists’ views about therapies, and new prescribing and treatment patterns and trends.”
Mid-Sized Biopharma Company
“MDoutlook’s great work helped us gain input for one of our pharma client brands in the immuno-oncology space. They connected us with the right oncologists who were more familiar with our brand than we expected, so the feedback was extremely valuable! All of the doctors were engaged, contributed to the conversation, and were very knowledgeable about immunotherapies.”
Major Pharma/Healthcare Branding Agency
“MDoutlook provided us critically valuable intelligence on the perspectives of highly influential oncologists about multiple myeloma therapies and treatments”.
Growing Oncology Diagnostics Company
“MDoutlook gave us very deep, spot-on insights from the most highly knowledgeable and respected oncologists specializing in uveal melanoma, which provided important guidance to our portfolio strategy.”
Early Stage Biotech Company
In recent conversations with pharma companies and healthcare marketing agencies about their global market intelligence-gathering methods, MDoutlook has been hearing a rising concern about whether they are both reaching the right oncologists in the U.S. and other key countries and whether they are getting the right answers to the right questions from them. Some have even told us that they get the same answers from the same physicians on every research project!
One key driver is that many market research organizations rely on third party physician panels and databases, giving them little control over the quality of respondents other than through screening questions. And answers to screening questions can and will be manipulated by savvy respondents.
Another challenge is that often the same group of oncologists are participating in nearly every market research initiative, resulting in skewed responses from a less than representative sample of oncologists questioned. And a third and final challenge is that engaging the right oncologist does not yet mean that the right questions are being asked, and that real-world evidence and insights are gathered.
Some key red flags that could result in questionable research findings include:
- Are you comfortable with how well you know the oncologists the research will engage prior to screening?
- Is your valuable physician panel time preoccupied with screening questions?
- Do you have to teach your market research partner about the intricacies of oncology, so they know the right questions to ask?
- Does the research partner have solid anchor points to other data sources and existing insights to triangulate and corroborate their research?
Working with MDoutlook, you never have to question what oncologists will say about your brand and your product portfolio because we have the most robust oncologist panel in the industry, put together by our staff physicians who engage with them on a regular basis. Because our research is designed by physicians for physicians, you never have to doubt the quality of the oncologist intelligence you are getting.
Thanks to detailed information on each panelist, gathered from the panelists themselves and supplemented by research through human analyst and machine-learning methodologies, we know exactly whom to target for which research, and we triangulate responses with previously gathered physician profile information and engagements ensuring the validity and robustness of our real-world insights.
As a result, we give you a blueprint of exactly which oncologists to connect with based on your portfolio specialty and strategic needs – oncologists that know your space inside and out and can share that extensive knowledge and work in a transparent and forthcoming way, so you can confidently make the decisions you need to about your portfolio.
Take the guesswork out of your oncologist insights research and contact the team at MDoutlook today.
MDoutlook announces the launch of its latest syndicated research study in which U.S. and international oncologists provide their perspectives on who, why and how the industry demonstrates leadership in advancing cancer treatment and care.
The Pharmaceutical Company Ranking in Oncology addresses and provides:
- what the oncologist community views as best practices by pharma in support, engagement and communication in improving cancer patient treatment and care
- who and what exemplifies leadership in addressing today’s top cancer care challenges
- additional specific oncologist views on pharma breast cancer leadership
- a self-assessment benchmarking tool for improving and enhancing current oncologist community outreach and support
- an optional study on oncologist views and usage of recently-launched breast cancer treatment therapies
Additional study details:
> comprehensive quantitative and qualitative research conducted:
> more than 100 medical oncologists interviewed via online (U.S. and Europe-based)
> top international experts recognized for their leadership in oncology interviewed by phone
> oncologist ranking criteria across 9 categories including innovation, sales reps and MSL support
> analysis available by U.S. and E.U. regions
> option to purchase entire syndicated study or customized reports tied to specific data within the study
> entire syndicated study and requested customized reports available within 3 days of purchase
> please click here to read more study details and how to order
Contact John Kane at [email protected] or at +1.814.325.9945 for inquiries about and/or to purchase this research.
NOW AVAILABLE: Impact of New Breast Cancer Data Announcements at ESMO 2017
Newly published syndicated report available on the impact of new breast cancer data presented at ESMO 2017:
> compare sponsored symposia
> get a read on expert sessions focused on HER2+ve adjuvant and neo-breast cancer treatments
> gain insights on poster and presentations on breast cancer at ESMO 2017, including perceptions of current breast cancer biosimilars
> assess awareness and impact of clinical trial data in specific breast cancer studies
> please click on this link to learn more